ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1930

Outcomes of Lupus-Related Glomerular and Tubulointerstitial Disease: Analysis of the National Inpatient Sample

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Edigin, Ehizogie, John H Stroger Hospital of Cook County, Chicago, Illinois, United States
  • Eseaton, Precious, University of Benin Teaching Hospital, Benin City, Edo, Nigeria

The study aims to compare the differences in outcomes of hospitalizations for Systemic Lupus Erythematosus (SLE) with glomerular and tubulointerstitial related renal disease. The outcomes compared were inpatient mortality, hospital length of stay (LOS), and total hospital charges.


Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 Database. NIS is the largest inpatient hospitalization database in the United States (U.S). The NIS was searched for adult SLE hospitalizations with lupus-related glomerular and tubulointerstitial disease as principal or secondary diagnosis using ICD-10 codes. The analysis was done using STATA. Multivariate logistic and linear regression analysis was used accordingly to adjust for confounders for the outcomes.


There were combined 71 million discharges included in the 2016 and 2017 NIS database. 51,875 hospitalizations were for adult patients, who had either a principal or secondary ICD-10 code for SLE with lupus-related renal disease. 51,525 (99.3%) and 350 (0.7%) of these hospitalizations were for SLE with lupus-related glomerular and tubulointerstitial disease respectively. The mean age for SLE with lupus-related glomerular disease was 40.6 vs 44.2 years for lupus-related tubulointerstitial disease (P=0.084). 7,060 adult SLE hospitalizations resulted in inpatient mortality. 1,110 (2.14%) of the deaths occurred in SLE with lupus-related glomerular disease. The number of deaths for lupus-related tubulointerstitial disease was less than 10, hence it was omitted during the analysis by STATA. SLE with lupus-related glomerular disease had similar LOS (6.8 vs 6.7 days, p=0.865) and total hospital charges ($79,718 vs $83,006, p=0.961) compared to those with tubulointerstitial disease.


SLE with glomerular disease makes up the vast majority of SLE with lupus-related renal disease hospitalizations. Almost all the in-hospital deaths of SLE patients with lupus-related renal disease occurred in SLE with glomerular disease. LOS and total hospital charges were similar between hospitalizations for SLE with lupus-related glomerular and tubulointerstitial diseases.